# Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

> **NCT07394062** · — · RECRUITING · sponsor: **Gazi University** · enrollment: 400 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer, Stage IV
- Metastatic Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab (1mg/kg)

## Key facts

- **NCT ID:** NCT07394062
- **Lead sponsor:** Gazi University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-08
- **Final completion:** 2028-02
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07394062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07394062, "Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07394062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*